JP2024513522A5 - - Google Patents
Info
- Publication number
- JP2024513522A5 JP2024513522A5 JP2023562566A JP2023562566A JP2024513522A5 JP 2024513522 A5 JP2024513522 A5 JP 2024513522A5 JP 2023562566 A JP2023562566 A JP 2023562566A JP 2023562566 A JP2023562566 A JP 2023562566A JP 2024513522 A5 JP2024513522 A5 JP 2024513522A5
- Authority
- JP
- Japan
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163172414P | 2021-04-08 | 2021-04-08 | |
| US63/172,414 | 2021-04-08 | ||
| US202163290359P | 2021-12-16 | 2021-12-16 | |
| US63/290,359 | 2021-12-16 | ||
| PCT/US2022/023684 WO2022216831A1 (en) | 2021-04-08 | 2022-04-06 | Treatment of cancer with nk cells and a her2 targeted antibody |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2024513522A JP2024513522A (ja) | 2024-03-25 |
| JP2024513522A5 true JP2024513522A5 (https=) | 2025-04-14 |
| JPWO2022216831A5 JPWO2022216831A5 (https=) | 2025-04-14 |
Family
ID=83545892
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023562566A Pending JP2024513522A (ja) | 2021-04-08 | 2022-04-06 | Ｎｋ細胞およびｈｅｒ２標的抗体を用いた癌治療 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20240197778A1 (https=) |
| EP (1) | EP4319771A4 (https=) |
| JP (1) | JP2024513522A (https=) |
| KR (1) | KR20240024048A (https=) |
| AU (1) | AU2022254689A1 (https=) |
| WO (1) | WO2022216831A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018124766A2 (ko) | 2016-12-28 | 2018-07-05 | 주식회사 녹십자랩셀 | 키메라 항원 수용체 및 이를 발현하는 자연 살해 세포 |
| EP3633029A4 (en) | 2017-05-26 | 2021-06-09 | Green Cross Lab Cell Corporation | METHOD OF DEVELOPING A NATURAL KILLER CELL USING A T-CELL |
| US12116417B2 (en) | 2017-11-14 | 2024-10-15 | GC Cell Corporation | Anti-HER2 antibody or antigen-binding fragment thereof, and chimeric antigen receptor comprising same |
| US11649294B2 (en) | 2017-11-14 | 2023-05-16 | GC Cell Corporation | Anti-HER2 antibody or antigen-binding fragment thereof, and chimeric antigen receptor comprising same |
| MY199770A (en) | 2018-11-14 | 2023-11-22 | Green Cross Lab Cell Corp | Method for culturing cord blood-derived natural killer cells using transformed t cells |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7171433B2 (ja) * | 2015-10-30 | 2022-11-15 | ザ ユナイテッド ステイツ オブ アメリカ， アズ リプレゼンテッド バイ ザ セクレタリー， デパートメント オブ ヘルス アンド ヒューマン サービシーズ | Ｈｅｒ－２発現固形腫瘍の処置のための組成物および方法 |
| CN107267454B (zh) * | 2016-04-07 | 2025-05-23 | 内蒙古原生元生物科技有限公司 | 一种脐血nk细胞的体外扩增方法及其试剂盒与应用 |
| AU2017268839A1 (en) * | 2016-05-27 | 2018-11-29 | Laboratoire Francais Du Fractionnement Et Des Biotechnologies | Combination of anti-CD20 antibody, P13 kinase-delta selective inhibitor, and BTK inhibitor to treat B-cell proliferative disorders |
| WO2018124766A2 (ko) * | 2016-12-28 | 2018-07-05 | 주식회사 녹십자랩셀 | 키메라 항원 수용체 및 이를 발현하는 자연 살해 세포 |
| EP4474391A3 (en) * | 2018-05-14 | 2025-02-26 | Indapta Therapeutics, Inc. | Subsets of human natural killer cells with enhanced antibody-directed immune responses |
-
2022
- 2022-04-06 AU AU2022254689A patent/AU2022254689A1/en not_active Abandoned
- 2022-04-06 US US18/285,647 patent/US20240197778A1/en active Pending
- 2022-04-06 KR KR1020237038625A patent/KR20240024048A/ko not_active Withdrawn
- 2022-04-06 WO PCT/US2022/023684 patent/WO2022216831A1/en not_active Ceased
- 2022-04-06 EP EP22785376.9A patent/EP4319771A4/en active Pending
- 2022-04-06 JP JP2023562566A patent/JP2024513522A/ja active Pending